BCA-101 is under clinical development by Bicara Therapeutics and currently in Phase II for Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Squamous Cell Carcinoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BCA-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BCA-101 is under development for the treatment of solid tumors like squamous cell lung cancer (SqCLC), squamous cell carcinoma of the head and neck (HNSCC), RAS wild-type microsatellite stable Colorectal carcinoma (RAS WT MSS CRC), squamous cell carcinoma of the anal canal (SCCAC), glioblastoma (GBM), gastric cancer, and any solid tumor with a KRAS G12D or G13D mutation any solid tumor with EGFR amplification including epithelial ovarian cancer, hepatocellular carcinoma (HCC), Anaplastic Thyroid Cancer (ATC) and pancreatic cancer. The drug candidate is fusion protein of a monoclonal antibody against EGFR with TGF beta 2 receptor fragment that binds and neutralizes TGF beta. It is developed based on technology platform which involves discovery and development of targeted immunoconjugates. It is administered intravenously. It acts by targeting EGFR and TGF beta. This program was also under development for the treatment of infectious diseases.
Bicara Therapeutics overview
Bicara Therapeutics, is a clinical-stage biotechnology company developing dual-action biologics designed to spur a potent and durable immune response in the tumor microenvironment. The company is headquartered in United States.
For a complete picture of BCA-101’s drug-specific PTSR and LoA scores, buy the report here.